A Prospective Phase I and II Trial of Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy
Phase of Trial: Phase I/II
Latest Information Update: 10 Dec 2019
Price : $35 *
At a glance
- Drugs Abemaciclib (Primary) ; Nivolumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 30 May 2019 Status changed from not yet recruiting to recruiting.
- 12 Apr 2019 Planned End Date changed from 31 Mar 2022 to 30 Jun 2022.
- 12 Apr 2019 Planned primary completion date changed from 31 Mar 2022 to 30 Jun 2022.